TY - JOUR AU - Kovács, Balázs AU - Szemerédi, Nikoletta AU - Csikós, Orsolya AU - Kiss, Tivadar AU - Veres, Katalin AU - Spengler, Gabriella AU - Csupor-Löffler, Boglárka AU - Csupor, Dezső TI - Chemical composition, antimicrobial and antiproliferative activity of the essential oil from Ambrosia artemisiifolia L JF - JOURNAL OF ESSENTIAL OIL RESEARCH J2 - J ESSENT OIL RES VL - 36 PY - 2024 IS - 1 SP - 30 EP - 42 PG - 13 SN - 1041-2905 DO - 10.1080/10412905.2024.2303449 UR - https://m2.mtmt.hu/api/publication/34501021 ID - 34501021 LA - English DB - MTMT ER - TY - JOUR AU - Laczkó-Zöld, Eszter AU - Csupor-Löffler, Boglárka AU - Kolcsár, Edina-Blanka AU - Ferenci, Tamás AU - Nan, Monica AU - Tóth, Barbara AU - Csupor, Dezső TI - The metabolic effect of Momordica charantia cannot be determined based on the available clinical evidence. a systematic review and meta-analysis of randomized clinical trials TS - a systematic review and meta-analysis of randomized clinical trials JF - FRONTIERS IN NUTRITION J2 - FRONT NUTR VL - 10 PY - 2024 PG - 11 SN - 2296-861X DO - 10.3389/fnut.2023.1200801 UR - https://m2.mtmt.hu/api/publication/34496994 ID - 34496994 N1 - * Megosztott szerzőség AB - Several studies have shown that Momordica charantia L. (Cucurbitaceae, bitter melon) has beneficial effects on metabolic syndrome (MetS) parameters and exerts antidiabetic, anti-hyperlipidemic, and anti-obesity activities. Since the findings of these studies are contradictory, the goal of this systematic review and meta-analysis was to assess the efficacy of bitter melon in the treatment of metabolic syndrome, with special emphasis on the anti-diabetic effect. Embase, Cochrane, PubMed, and Web of Science databases were searched for randomized controlled human trials (RCTs). The meta-analysis was reported according to the PRISMA statement. The primary outcomes of the review are body weight, BMI, fasting blood glucose, glycated hemoglobin A1c, systolic blood pressure, diastolic blood pressure, serum triglyceride, HDL, LDL, and total cholesterol levels. Nine studies were included in the meta-analysis with 414 patients in total and 4–16 weeks of follow-up. In case of the meta-analysis of change scores, no significant effect could be observed for bitter melon treatment over placebo on fasting blood glucose level (MD = −0.03; 95% CI: −0.38 to 0.31; I 2 = 34%), HbA1c level (MD = −0.12; 95% CI: −0.35 to 0.11; I 2 = 56%), HDL (MD = −0.04; 95% CI: −0.17 to 0.09; I 2 = 66%), LDL (MD = −0.10; 95% CI: −0.28 to 0.08; I 2 = 37%), total cholesterol (MD = −0.04; 95% CI: −0.17 to 0.09; I 2 = 66%,), body weight (MD = −1.00; 95% CI: −2.59–0.59; I 2 = 97%), BMI (MD = −0.42; 95% CI: −0.99–0.14; I 2 = 95%), systolic blood pressure (MD = 1.01; 95% CI: −1.07–3.09; I 2 = 0%) and diastolic blood pressure levels (MD = 0.24; 95% CI: −1.04–1.53; I 2 = 0%). Momordica treatment was not associated with a notable change in ALT, AST, and creatinine levels compared to the placebo, which supports the safety of this plant. However, the power was overall low and the meta-analyzed studies were also too short to reliably detect long-term metabolic effects. This highlights the need for additional research into this plant in carefully planned clinical trials of longer duration. LA - English DB - MTMT ER - TY - JOUR AU - Ferencz, Elek AU - Spengler, Gabriella AU - Zupkó, István AU - Vollár, Martin AU - Zomborszki, Zoltán Péter AU - Kúsz, Norbert AU - Hohmann, Judit AU - Kovács, Balázs AU - Csupor, Dezső AU - Laczkó-Zöld, Eszter AU - Csupor-Löffler, Boglárka TI - Isolation of compounds from the roots of Ambrosia artemisiifolia and their effects on human cancer cell lines JF - ZEITSCHRIFT FÜR NATURFORSCHUNG C-A JOURNAL OF BIOSCIENCES J2 - Z NATURFORSCH C VL - 78 PY - 2023 IS - 7-8 SP - 299 EP - 305 PG - 7 SN - 0939-5075 DO - 10.1515/znc-2022-0239 UR - https://m2.mtmt.hu/api/publication/33742452 ID - 33742452 AB - Common ragweed (Ambrosia artemisiifolia L.) is an invasive plant in Europe with spreading use in the contemporary folk medicine. The chemical composition of the above-ground parts is extensively studied, however, the metabolites of the roots are less discovered. By multiple chromatographic purification of the root extracts, we isolated thiophene A (1), n-dodecene (2), taraxerol-3-O-acetate (3), α-linoleic acid (4), (+)-pinoresinol (5), and thiophene E (7,10-epithio-7,9-tridecadiene-3,5,11-triyne-1,2-diol) (6). The 1H NMR data published earlier for 1 were supplemented together with the assignment of 13C NMR data. Thiophene E (6), which is reported for the first time from this species, exerted cytotoxic and antiproliferative effects on A-431 epidermoid skin cancer cells, whereas taraxerol-3-O-acetate (3) and α-linoleic acid (4) had slight antiproliferative effect on gynecological cancer cell lines. Thiophene E (6) and taraxerol-3-O-acetate (3) displayed antiproliferative and cytotoxic effects on MRC-5 fibroblast cells. Thiophene E (6) exerted weak antibacterial activity (MIC 25 μg/mL) on MRSA ATCC 43300, on Staphylococcus aureus ATCC 25923, Escherichia coli AG100 and E. coli ATCC 25922 both thiophenes were inactive. Although the isolated compounds exerted no remarkable cytotoxic or antiproliferative activities, the effects on MRC-5 fibroblast cells highlight the necessity of further studies to support the safety of ragweed root. LA - English DB - MTMT ER - TY - JOUR AU - Bajtel, Ákos AU - Kiss, Tivadar AU - Tóth, Barbara AU - Kiss, Szabolcs AU - Hegyi, Péter AU - Vörhendi, Nóra AU - Csupor-Löffler, Boglárka AU - Gede, Noémi AU - Hohmann, Judit AU - Csupor, Dezső TI - The Safety of Dronabinol and Nabilone: A Systematic Review and Meta-Analysis of Clinical Trials JF - PHARMACEUTICALS J2 - PHARMACEUTICALS-BASE VL - 15 PY - 2022 IS - 1 PG - 15 SN - 1424-8247 DO - 10.3390/ph15010100 UR - https://m2.mtmt.hu/api/publication/32604937 ID - 32604937 LA - English DB - MTMT ER - TY - JOUR AU - Bali, Zsolt Kristóf AU - Bruszt, Nóra AU - Kőszegi, Zsombor AU - Nagy, Lili Veronika AU - Atlasz, Tamás AU - Kovács, Péter AU - Csupor, Dezső AU - Csupor-Löffler, Boglárka AU - Hernádi, István TI - Aconitum Alkaloid Songorine Exerts Potent Gamma-Aminobutyric Acid-A Receptor Agonist Action In Vivo and Effectively Decreases Anxiety without Adverse Sedative or Psychomotor Effects in the Rat JF - PHARMACEUTICS J2 - PHARMACEUTICS VL - 14 PY - 2022 IS - 10 PG - 15 SN - 1999-4923 DO - 10.3390/pharmaceutics14102067 UR - https://m2.mtmt.hu/api/publication/33117614 ID - 33117614 AB - Songorine (SON) is a diterpenoid alkaloid from Aconitum plants. Preparations of Aconitum roots have been employed in traditional oriental herbal medicine, however, their mechanisms of action are still unclear. Since GABA-receptors are possible brain targets of SON, we investigated which subtypes of GABA-receptors contribute to the effects of SON, and how SON affects anxiety-like trait behavior and psychomotor cognitive performance of rats. First, we investigated the effects of microiontophoretically applied SON alone and combined with GABA-receptor agents picrotoxin and saclofen on neuronal firing activity in various brain areas. Next, putative anxiolytic effects of SON (1.0–3.0 mg/kg) were tested against the GABA-receptor positive allosteric modulator reference compound diazepam (1.0–5.0 mg/kg) in the elevated zero maze (EOM). Furthermore, basic cognitive effects were assessed in a rodent version of the psychomotor vigilance task (PVT). Local application of SON predominantly inhibited the firing activity of neurons. This inhibitory effect of SON was successfully blocked by GABA(A)-receptor antagonist picrotoxin but not by GABA(B)-receptor antagonist saclofen. Similar to GABA(A)-receptor positive allosteric modulator diazepam, SON increased the time spent by animals in the open quadrants of the EOM without any signs of adverse psychomotor and cognitive effects observed in the PVT. We showed that, under in vivo conditions, SON acts as a potent GABA(A)-receptor agonist and effectively decreases anxiety without observable side effects. The present findings facilitate the deeper understanding of the mechanism of action and the widespread pharmacological use of diterpene alkaloids in various CNS indications. LA - English DB - MTMT ER - TY - JOUR AU - Kovács, Balázs AU - Szemerédi, Nikoletta AU - Kúsz, Norbert AU - Kiss, Tivadar AU - Csupor-Löffler, Boglárka AU - Tsai, Y-C AU - Spengler, Gabriella AU - Csupor, Dezső TI - Antiproliferative sesquiterpene lactones from Ambrosia artemisiifolia L JF - PLANTA MEDICA: NATURAL PRODUCTS AND MEDICINAL PLANT RESEARCH J2 - PLANTA MED VL - 88 PY - 2022 IS - 15 SP - 1533 EP - 1533 PG - 1 SN - 0032-0943 DO - 10.1055/s-0042-1759242 UR - https://m2.mtmt.hu/api/publication/33684363 ID - 33684363 LA - English DB - MTMT ER - TY - JOUR AU - Kovács, Balázs AU - Szemerédi, Nikoletta AU - Kúsz, Norbert AU - Kiss, Tivadar AU - Csupor-Löffler, Boglárka AU - Tsai, Yu-Chi AU - Rácz, Bálint AU - Spengler, Gabriella AU - Csupor, Dezső TI - Antiproliferative and cytotoxic effects of sesquiterpene lactones isolated from Ambrosia artemisiifolia on human adenocarcinoma and normal cell lines. JF - PHARMACEUTICAL BIOLOGY J2 - PHARM BIOL VL - 60 PY - 2022 IS - 1 SP - 1511 EP - 1519 PG - 9 SN - 1388-0209 DO - 10.1080/13880209.2022.2103574 UR - https://m2.mtmt.hu/api/publication/33049439 ID - 33049439 AB - Ambrosia artemisiifolia L. (Asteraceae) contains sesquiterpene lactones as characteristic secondary metabolites. Many of these compounds exert antiproliferative and cytotoxic effects.To isolate the sesquiterpene lactones from the aerial part of A. artemisiifolia and to elucidate their cytotoxic, antiproliferative and antibacterial effects.The compounds were identified by one-dimensional (1D) and 2D NMR, HR-MS spectroscopy from the methanol extract. Isolated compounds were investigated for their cytotoxic and antiproliferative effects on human colonic adenocarcinoma cell lines and human embryonal lung fibroblast cell line using MTT assay. The selectivity of the sesquiterpenes was calculated towards the normal cell line. To check the effect of drug interactions between compounds and doxorubicin, multidrug-resistant Colo 320 cells were used.A new seco-psilostachyinolide derivative, 1,10-dihydro-1'-noraltamisin, and seven known compounds were isolated from the methanol extract. Acetoxydihydrodamsin had the most potent cytotoxic effect on sensitive (Colo205) cell line (IC50 = 7.64 µM), also the strongest antiproliferative effect on Colo205 (IC50 = 5.14 µM) and Colo320 (IC50 = 3.67 µM) cell lines. 1'-Noraltamisin (IC50 = 8.78 µM) and psilostachyin (IC50 = 5.29 µM) showed significant antiproliferative effects on the multidrug-resistant Colo320 cell line and had moderate selectivity against human embryonal lung fibroblast cell line. Psilostachyin C exhibited cytotoxic effects on Colo205 cells (IC50 = 26.60 µM). None of the isolated compounds inhibited ABCB1 efflux pump (EP; P-glycoprotein) or the bacterial EPs.Acetoxydihydrodamsin, 1'-noraltamisin, and psilostachyin showed the most remarkable cytotoxic and antiproliferative activity on tumour cell lines and exerted selectivity towards MRC-5 cell line. LA - English DB - MTMT ER - TY - JOUR AU - Kovács, Balázs AU - Hohmann, Judit AU - Csupor-Löffler, Boglárka AU - Kiss, Tivadar AU - Csupor, Dezső TI - A comprehensive phytochemical and pharmacological review on sesquiterpenes from the genus Ambrosia JF - HELIYON J2 - HELIYON VL - 8 PY - 2022 IS - 7 PG - 33 SN - 2405-8440 DO - 10.1016/j.heliyon.2022.e09884 UR - https://m2.mtmt.hu/api/publication/32948511 ID - 32948511 LA - English DB - MTMT ER - TY - CHAP AU - Roza, Orsolya AU - Csupor-Löffler, Boglárka AU - Tóth, Barbara ED - Szarvasházi, Judit TI - 8.4 Gyógynövények/drogok a betegségek megelőzésében és terápiájában - 1. rész T2 - Gyógyszertári ismeretek (szak)asszisztensek részére 7. kötet PB - Országos Kórházi Főigazgatóság CY - Budapest SN - 9789639661646 PY - 2022 SP - 44 UR - https://m2.mtmt.hu/api/publication/33267338 ID - 33267338 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Tóth, Barbara AU - Jávorházy, András AU - Nyirády, Péter AU - Csupor-Löffler, Boglárka AU - Birinyi, Péter AU - Zhanel, George AU - Naber, Kurt AU - Länger, Reinhard AU - Vörhendi, Nóra AU - Gede, Noémi AU - Váncsa, Szilárd AU - Hegyi, Péter AU - Csupor, Dezső TI - Bearberry in the treatment of acute uncomplicated cystitis (BRUMI) : protocol of a multicentre, randomised double-blind clinical trial JF - BMJ OPEN J2 - BMJ OPEN VL - 12 PY - 2022 IS - 6 PG - 7 SN - 2044-6055 DO - 10.1136/bmjopen-2021-057982 UR - https://m2.mtmt.hu/api/publication/32911943 ID - 32911943 AB - Bearberry (Arctostaphylos uva-ursi) leaf is available as a treatment of uncomplicated cystitis in several European countries. The antimicrobial activity of its extracts and some of its individual constituents has been observed in vitro; however, the efficacy of bearberry compared with standard antimicrobial therapy has not been assessed yet.The objective of the study is to assess the safety and non-inferiority of bearberry as an alternative therapy in the treatment of acute uncomplicated cystitis in comparison with standard antibiotic therapy (fosfomycin).This is a randomised controlled double-blinded multicentre trial. Eligible patients will be premenopausal women with a sum score of ≥6 for the typical acute uncomplicated cystitis symptoms (frequency, urgency, painful urination, incomplete emptying, suprapubic pain and visible haematuria) reported on the Acute Cystitis Symptom Score (ACSS) typical domain and pyuria. Patients will be randomly assigned to receive 3 g single dose of fosfomycin powder and two placebo tablets three times a day for 7 days or B a single dose of placebo powder and two tablets containing a dry extract of Uvae ursi folium. At least 504 patients (allocated as 1:1) will need to be enrolled to access non-inferiority with a non-inferiority limit of 14% for the primary endpoint.Improvement of symptoms of uncomplicated cystitis (based on the ACSS score) at day 7 is defined as the primary endpoint, whereas several secondary endpoints such as the number and ratio of patients with bacteriuria at day 7, frequency and severity of side effects; recurrence of urinary tract infection, concurrent use of other over the counter (OTC) medications and food supplements will be determined to elucidate more detailed differences between the groups. The number of recurrences and medications taken for treatment will be monitored for a follow-up period of 90 days (80-100 days).This study has been approved by the Scientific and Research Ethics Committee of the Hungarian Medical Research Council (IV/4225-1/2021/EKU). The results will be disseminated by publication of peer-reviewed manuscripts.NCT05055544. LA - English DB - MTMT ER -